Safety of cangrelor and transition to oral P2Y 12 inhibitors in patients undergoing percutaneous coronary intervention: the ARCANGELO study.

Leonardo De Luca Paolo CalabròPiera CapranzanoCarlo Di MarioFabio ChirilloCristina RolfoAlberto MenozziMaurizio MenichelliLeonardo BologneseGiuseppe Musumeci

Published in: European heart journal open (2023)

inhibitors are confirmed as safe and effective in daily practice.

Keyphrases